===
Siegfried AG / Key word(s): Acquisition
Siegfried to acquire an early-phase CDMO in Wisconsin (US) to strengthen its Drug Substances service offering
12-Jun-2024 / 06:30 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.
-- Siegfried to acquire a CDMO specialized in early-phase development and manufacturing services in Grafton,
Wisconsin (US)
-- The new site is set to strengthen Siegfried's customer offering for Drug Substances in terms of
capabilities and geography
-- Siegfried will further develop the site into its North American Siegfried Acceleration Hub for
early-phase CDMO services, to generate attractive growth opportunities

Siegfried (SIX: SFZN), a leading global Contract Development and Manufacturing Organization (CDMO) for the
pharmaceutical industry headquartered in Zofingen (Switzerland), has signed binding agreements with Curia Global for
the acquisition of an early-phase CDMO site in Grafton, Wisconsin (US).

The new site, which specializes in early-phase development and manufacturing services with an experienced team of more
than 80 employees, is set to strengthen Siegfried's customer offering for Drug Substances in terms of capabilities and
geographical coverage. Siegfried intends to develop the site into a best-in-class hub for early-phase CDMO services for
its global customer base, including services for projects with highly potent APIs. Subject to customary closing
conditions, the transaction is expected to close by July 1, 2024.

Reto Suter, CEO ad interim and CFO of Siegfried, commented: "With this acquisition, we enhance our offering with
early-stage development services for Drug Substances and become even more relevant and attractive to our customers.
Siegfried now offers an integrated range of services from early-stage development to commercial production of APIs
through to the manufacturing of fully formulated Drug Products. This transaction will generate attractive opportunities
and will further accelerate our growth story."

The acquisition will strengthen Siegfried's position in the United States, the world's largest pharmaceutical market,
and enables Siegfried to provide comprehensive support to customers in the pre-clinical and clinical development and
manufacturing of Drug Substances. This further expands Siegfried's offering, particularly for small and medium-sized
pharmaceutical companies. The focus on early-phase CDMO services will further strengthen Siegfried's Drug Substance
pipeline by capturing additional attractive opportunities in their early stage, creating significant growth
opportunities in the future.

The acquisition is financed from existing funds. The outlook for 2024 and the mid-term financial targets remain
unchanged.

Media Release English version (PDF)
Media Release German version (PDF)
Analyst Call
Siegfried will host an analyst call on June 12 at 10:00 am CEST. To participate in the analyst call, please follow the
dial-in information below.
Analyst Call presentation (PDF)
Click here to join the meeting
Meeting ID: 359 199 908 234
Passcode: iCWXMQ

Dial in by phone
+41 43 216 37 72,,740164912# Switzerland, Zurich/Zürich/Zurigo
Find a local number
Phone conference ID: 740 164 912#
Further Information
Media release on website
Contact

Financial Analysts:                                  Media: 
Dr. Reto Suter                                       Peter Stierli 
Chief Financial Officer                              Head Corporate Communications 
reto.suter@siegfried.ch                              peter.stierli@siegfried.ch 
Tel. +41 62 746 11 35                                Tel. +41 62 746 15 51 

Siegfried Holding AG
Untere Bruehlstrasse 4

CH-4800 Zofingen

===
About Siegfried

The Siegfried Group is a global life sciences company with sites in Switzerland, Germany, Spain, France, Malta, the USA and China. In 2023, the company achieved sales of CHF 1.272 billion and employed on 31.12.2023 more than 3700 people at twelve sites on three continents. Siegfried Holding AG is publicly listed on the SIX Swiss Exchange (SIX: SFZN).

Siegfried is active in manufacturing pharmaceutical APIs (and their intermediates) as well as drug products (tablets, capsules, sterile vials, ampoules, cartridges and ointments) for the pharmaceutical industry and provides development services. Cautionary Statements Regarding Forward-Looking Statements This media release includes statements concerning the future. They are based on assumptions and expectations that may prove to be wrong. They should be considered with due caution as, by definition, they contain known and unknown risks, insecurities and other factors which could result in a difference in the actual results, financial situation, developments or the success of Siegfried Holding AG or Siegfried Group from the explicit or implicit assumptions made in these statements.

expect more

Siegfried AG Untere Brühlstrasse 4 4800 Zofingen, Switzerland +41 62 746 11 11 info@siegfried.ch www.siegfried.ch

-----------------------------------------------------------------------------------------------------------------------

End of Inside Information

-----------------------------------------------------------------------------------------------------------------------

===

Language:     English 
Company:      Siegfried AG 

Untere Brühlstrasse 4
4800 Zofingen
Switzerland

Phone:        +41 62 746 11 11 
E-mail:       info@siegfried.ch 
Internet:     https://www.siegfried.ch 
ISIN:         CH0014284498 
Listed:       SIX Swiss Exchange 
EQS News ID:  1915639 

End of Announcement EQS News Service
===
1915639 12-Jun-2024 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1915639&application_name=news

END) Dow Jones Newswires

June 12, 2024 00:31 ET (04:31 GMT)